Drugs / BEV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02330562 | Apr 2015 → Jun 2021 | glioblastoma | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02330562 ↗ |
| Route | Intravenous | “BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.” NCT02330562 ↗ |